The clinical efficacy and safety of MK-0787/MK-0791 were compared with piperacillin (PIPC) in respiratory tract infections by a well controlled study. Drugs were administered by intravenous drip infusion twice a day for 14 days, at a daily of 1 g/1 g of MK-0787/MK-0791 or 4 g of PIPC.
The following results were obtained.
1. Out of 367 patients (183 administered MK-0787/MK-0791, 184 PIPC) included in this trial, the clinical efficacy of 301 patients (155 received MK-0787/MK-0791, 146 PIPC) was evaluated by the committee members.
2. The clinical efficacy rates in all cases evaluated by the committee members were 80.0% in MK-0787/MK-0791 and 71.7% in PIPC, respectively, and no significant difference was observed between the two drugs. Wheras, the clinical efficacy rates evaluated by the attending physicians were 82.0% in MK-07871/MK-0791 and 72.0% in PIPC, and significant difference was observed between the two drugs.
3. No significant difference was observed between the clinical efficacy of the two drugs evaluated by the committee members in patients with pneumonia or pulmonary suppuration. But in patients with chronic respiratory tract infections, the clinical efficacy rates were 83.5% in MK-0787/MK-0791 and 63.0% in PIPC, respectively, therefore MK-0787/MK-0791 was significantly superior to PIPC. The clinical efficacy evaluated by both the attending physicians and the committee members in those patients were observed to be similar.
4. The clinical and bacteriological efficacy against causative organisms in all cases were observed to have no significant difference between the two drugs, but MK-0787/MK-0791 was significantly superior to PIPC in single infections by
P. aeruginosa.
5. No significant difference was observed between the two drugs in regard to side effects or abnormality in laboratory findings.
6. The usefulness of MK-0787/MK-0791 was superior to PIPC in all cases and in patients with chronic respiratory tract infections judged by committee members, and in patients with chronic respiratory tract infections judged by attending physicians.
From these results it was concluded that MK-0787/MK-0791 is an extremely useful drug in the treatment of respiratory tract infections.
View full abstract